quinazolines has been researched along with megestrol acetate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audhuy, B; El-Hariry, I; Gardner, JP; Gore, M; Harper, P; Hawkins, R; Machiels, JP; Pétavy, F; Ravaud, A; Rolland, F; Schöffski, P; von der Maase, H; Zantl, N | 1 |
| Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S | 1 |
2 trial(s) available for quinazolines and megestrol acetate
| Article | Year |
|---|---|
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; Kidney Neoplasms; Lapatinib; Male; Megestrol Acetate; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tamoxifen | 2008 |
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult | 2013 |